The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study

To clarify the effect of Two-field or Three-field Lymphadenectomy on the survival of esophageal squamous cell carcinoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Esophageal Cancer Digestive System Diseases Digestive System Neoplasms Esophageal Diseases Esophageal Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Head and Neck Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sichuan Cancer Hospital

Chengdu, Sichuan, 610041, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1. Men and women aged 18-85 years
2. Histologically confirmed primary thoracic esophageal squamous cell carcinoma,
3. Staging PT1b-4A, N0-3, M0 AJCC eighth edition
4. Excluding lymph node dissection < 15, (meeting the guideline criteria)
5. The tumor located in the lower middle thoracic.

Exclusion criteria

1. Patients with a history of previous thoracic and abdominal surgery that may affect lymphatic reflux
2. Patients with distant metastasis confirmed by imaging
3. Patients with obvious surgical contraindications.

Treatment and study plan

Since the data were collected retrospectively, there were no interventions

Diagnostic Test

Since the data were collected retrospectively, there were no interventions

Primary outcomes

The number of lymph nodes

Time frame: 2010.1.1-2017.12.30

Surgical data were retrospectively collected

Sponsors and collaborators

Lead sponsor

Yongtao Han

Other

Registry information

Official study title

The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: A Single Center Retrospective Analysis

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Nov 15, 2022
Registry last updated: Nov 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed